Apollomics was founded as a biotechnology company with the vision to become a global leader in the development of novel medicines for cancer patients. With operations in both the U.S. and China, we believe we are well positioned to unlock synergies by leveraging the strengths of partnerships with other biotechnology companies in the East and the West.

We have established a physical presence in China in both Hangzhou and Shanghai. Our Hangzhou location houses offices, laboratories, dormitory as well as a clinical development team to support the advancement of our preclinical and clinical development programs. Our deep roots in both technology centers allow us to combine in-house innovations and outside partnerships to develop novel cancer therapies for patients in China and globally. We are well situated to explore solutions for drug-resistant and difficult-to-treat cancers.